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Abstract 
Retinoblastoma (RB) is a rare pediatric cancer commonly diagnosed in patients at a very 
young age. New therapies for this disease are emerging that involve some degree of sedation, 
requiring anesthesia providers to be involved in their care. Intraarterial chemotherapy (IAC) is 
one of these new exciting treatment options and requires general anesthesia. Multiple studies and 
case reports have reported a sudden decrease in pulmonary compliance during IAC for RB and 
attribute this response to the trigemino-cardiac reflex (TCR). Once this event occurs, patients 
experience associated hypoxemia, hypotension, bradycardia, and cardiovascular collapse. A 
systematic literature review was aimed at educating the anesthesia provider on the signs and 
symptoms, pathophysiology, diagnosis and treatment options for patients with RB as well as 
identifying possible risk factors for developing this phenomenon.  
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Anesthetic implications of intraarterial chemotherapy for retinoblastoma  
Retinoblastoma (RB) is a rare malignancy and is the most commonly diagnosed ocular 
cancer among pediatric patients. It can be a devastating disease that may lead to death if not 
treated effectively (Rao & Hanover, 2017). Intraarterial chemotherapy (IAC) is a relatively new 
treatment option for RB. It is performed in interventional neuroradiology and requires general 
anesthesia with tracheal intubation and muscle relaxation. Patients need to remain completely 
still as fluoroscopy is used to guide catheter placement in the ophthalmic artery. During this 
procedure, patients may develop a sudden and profound decrease in pulmonary compliance that 
can lead to hypoxemia, bradycardia, hypotension and ultimately cardiovascular collapse if not 
treated appropriately (Scharoun, Han & Gobin, 2016). In some case reports, this 
cardiorespiratory event was referred to as the trigemino-cardiac reflex (TCR). This systematic 
literature review will discuss RB and its anesthetic implications, define the TCR, and identify 
trends in the literature that may detect which patients may be at risk for developing this 
cardiorespiratory event. Finally, this paper will also educate the anesthesia provider on how to 
prepare, anticipate, identify and treat the sudden and profound decrease in pulmonary 
compliance that can occur during IAC for RB.  
Methods 
 A systematic literature review was performed using PubMed and Cinahl databases. The 
following key words were used: intraarterial chemotherapy, retinoblastoma, trigemino-cardiac 
reflex, cardiopulmonary reflex, pulmonary compliance, pediatric anesthesia, and anesthesia 
outside of the operating room. Articles from 2014-2019 were evaluated for relevance. Two 
articles from 2013 were included as they were considered “landmark studies.”  
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Literature Review 
Pathophysiology 
RB is a rare pediatric cancer that results from mutations to specific genes during 
development. RB occurs in 1 in every 15,000 to 18,000 live births and represents 3% of all 
childhood cancers. The tumor begins in the retina and then extends outwards to surrounding 
structures (Rao & Hanover, 2017). Normal ocular anatomy can be seen in Figure 1. A tumor 
suppressor gene (RBL) has been identified in association with RB.  The RBL gene is located on 
chromosome 13 (13q) and loss of function mutations to this gene causes nonsense codons or 
frameshifts. These changes cause overwhelming tumor cell growth. RB1 gene deletion syndrome 
may also occur. However, it is due to the complete lack of chromosome 13q and leads not only 
to RB, but also other neurodevelopment delays as well as varying degrees of physical 
abnormalities (Rao & Hanover, 2017).   
While the RBL gene is responsible for the majority of cases, this type of cancer can also 
be due to a genetic mutation, 30-40% which are heritable and 60-70% which are sporadic. In 
what is considered "heritable" RB, there are two genetic mutations that occur that lead to the 
disease: 1) mutation of the germ cell, which makes all cells in the body prone to RB and other 
cancers, and/or 2) mutation of the retinal cell, which can only result in RB. The mutation of the 
retinal cell occurs on the same gene as the mutation of the germ cell, but on the paired 
chromosome.  Patients with this diagnosis are usually diagnosed within the first month of life. In 
sporadic RB both mutations occur in the retinal cell, specifically and is diagnosed around the age 
of two (Rao & Hanover, 2017).  
All of these mutations cause gene underactivity and create an environment in which 
cancer cell proliferation is promoted. Under normal conditions, the cell cycle has certain “check 
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points” that either allow the cell to continue to 
grow if developing normally or stops cell growth 
if there is some sort of malfunction in the cell 
structure or genetic coding. When these naturally 
occurring “check points” do not function as they 
are supposed to, such as in the case with the gene 
malfunctions that occur with RB, abnormal cell 
proliferation occurs at an uncontrolled rate, and 
therefore cancerous tumors develop (Grossman & 
Porth, 2014). This is exactly what occurs in 
patients with RB, and therefore tumor cells 
proliferate.  
Signs and Symptoms 
RB is usually diagnosed after 
significant disease progression has taken 
place. It can often go unrecognized by 
parents as children do not always have overt 
symptoms or exhibit any decline in vision or 
health (Almontaser, Ritchie, Madison & 
Jabbour, 2018). RB can affect only one or 
both eyes and is usually diagnosed by the age 
of 18, with 95% of diagnoses before the age 
of five (Rao & Hanover, 2017). The most 
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common sign of RB is leukocoria, also known as the “white pupillary reflex”. This is most often 
first noticed by parents when using flash photography in which the child's pupils appear white. 
The second most common feature is strabismus, with other associated symptoms including poor 
vision, red painful eye, vitreous hemorrhage, phthisis bulbi, sterile orbital cellulitis, and proptosis 
(Rao & Hanover, 2017). The further the progression of the disease, the more overt the symptoms 
become.  
Once diagnosed, in most cases, RB results 
in a uni- or multi-focal, dome-shaped retinal mass 
with dilated retinal vessels. The tumor starts as a 
small, transparent growth that is entirely 
intraretinal. In the retina, RB starts out as small 
tumors that are less than 3 mm. These tumors will 
then extend into the macula and vitreous body (Rao 
& Hanover, 2017.) These structures can be seen in 
Figure 1.  RB is considered extensive when either 
50% of the globe is occupied or it has invaded the 
optic nerve, choroid, sclera, orbit, or anterior 
chamber. As it grows, the tumor becomes opaque 
and white and extends away from the vitreous 
cavity or towards it. As the malignancy advances, 
clinical manifestations advance to the outside of the 
eye. (Rao & Hanover, 2017).  Figure 2 shows the 
clinical presentation of RB. A) exophytic growth 
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pattern with diffuse subretinal fluid; B) endophytic growth pattern with diffuse vitreous seeds, 
which are primary or secondary collections of tumor cells that are found in the avascular 
vitreous; C) advanced RB with neovascular glaucoma; and D) advanced RB with orbital 
cellulitis (Rao & Hanover, 2017). As the disease progresses, symptoms become more obvious 
and clinical manifestations more severe.  
Diagnosis 
Official diagnosis of RB is done through a routine eye exam by an ophthalmologist 
usually after leukocoria or other physical symptoms are noticed by parents. The extent of 
extraocular extension of RB is then evaluated with the use of imaging, including MRI and CT 
scan. Other tests include ultrasound, fluorescein angiography, and optical coherence tomography 
(Rao & Hanover, 2017). Pediatric patients do not generally undergo routine eye exams, unless 
under these circumstances. They are usually unable to cooperate or tolerate eye these exams or 
further imaging without some sort of sedation (Almontaser et al., 2018). Therefore, anesthesia 
providers are present for these cases and administer anesthetics ranging from moderate sedation 
to general anesthesia.  
Once a diagnosis is made and extent of tumor extension is evaluated, the tumor is then 
grouped and staged. The grouping system evaluates the extent of tumor size, location, severity, 
and presence of subretinal and vitreous seeds. The staging system, however, helps to predict 
survival in patients with RB. Favorable outcomes for eye preservation exist for patients deemed 
stage 0 & I. While patients who have stage IV are predicted to lose their eye and even their life. 
The International Classification of Retinoblastoma (ICRB) was created in 2003 and includes 
both grouping and staging (Almontaser et al., 2018). The ICRB is listed in Table 1.  
 
ANESTHETIC IMPLICATIONS OF INTRAARTERIAL CHEMO 8 
Treatment 
After a diagnosis is made, treatment is aimed at vision optimization, eye salvage, and 
survival. Treatment options include intravenous chemotherapy, periocular chemotherapy, 
intravitreal chemotherapy, radiation therapy, focal therapy, and IAC (Rao & Hanover, 2017). 
Figure 3 depicts the administration of these types of chemotherapy.  
Intravenous chemotherapy is a widely used form of chemotherapy and can be seen in 
Figure 3. Typically, six rounds of a combination of three drugs are administered: vincristine, 
etoposide, and carboplatin. This option has displayed very promising success rates, especially in 
less advanced cases. In ICRB groups A, B, and C, intravenous chemotherapy has success rates, 
defined as eye salvage, of 100%, 93%, and 90% respectively. In ICRB group D and E tumors, 
rates of regression and eye salvage with the standard triple-drug chemotherapy have been less 
than ideal. Fifty percent of group D eyes required additional treatments including external beam 
radiation therapy or enucleation (Rao & Hanover, 2017). While this is a promising treatment 
option for group A, B, and C eyes, effectiveness is less than ideal in group D and E eyes.  
Intravenous chemotherapy, however, comes with many side effects. The systemic effects 
of agents like vincristine, doxorubicin, carboplatin, and etoposide include nephrotoxicity, 
hepatotoxicity, cardiomyopathy, ototoxicity, and myelosuppression. It even puts patients at risk 
for developing other types of malignancies, especially leukemias (Monroy et al., 2014). These 
side effects can be devastating and often leave patients with secondary life-long medical 
conditions.  
Intravenous chemotherapy is usually administered via central vein through an indwelling 
port catheter or peripherally inserted central catheter. Placement of these lines requires 
ANESTHETIC IMPLICATIONS OF INTRAARTERIAL CHEMO 9 
anesthesia, from moderate sedation to general anesthesia, and therefore pediatric anesthesia 
providers are very much involved in the care of these patients.    
 Periocular chemotherapy is a treatment option for ICRB group D and E tumors that 
also have vitreous seeds. Through this approach, seen in Figure 3, chemotherapeutic agent is 
administered via a posterior sub-tendon injection in the quadrant of the eye that is closest to the 
vitreous seeds. These patients require a larger 
concentration of chemotherapeutic agent locally which 
can be achieved by this route on administration. 
Periocular chemotherapy achieves rapid levels of 
chemotherapeutic agent in the vitreous cavity within 
30 minutes at concentrations that are six to ten times 
higher than what intravenous chemotherapy may 
provide. When used in conjunction with high dose 
chemotherapy, this option has led to a 95% eye 
salvage rate in group C patients and a 70% eye salvage 
rate in group D patients (Rao & Hanover, 2017). 
Anesthesia providers are involved in these cases as the 
injection requires some degree of sedation or general 
anesthesia to ensure that the patient does not move and that the chemotherapeutic agent is not 
inadvertently injected in the wrong space.   
Intravitreal chemotherapy seen in Figure 3, is also a good option for patients who 
present with vitreous seeds. This method injects chemotherapeutic agent directly into the 
vitreous cavity, instead of the quadrant around it. Because of their lack of blood supply, vitreal 
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seeds can be very resistant to intravenous chemotherapy. Ineffective chemotherapeutic 
concentration in the vitreous cavity can result in persistent vitreous seeds, making intravitreal 
chemotherapy the desired treatment route. Melphalan is the chemotherapeutic agent used in this 
technique. With its use, vitreous seed regression from 85-100% has been reported with 
associated globe salvage in 80-100% of eyes (Rao & Hanover, 2017). This procedure, however, 
is painful and requires some degree of sedation or general anesthesia. 
Radiation therapy is also an effective, as well as a potentially curative, treatment option 
because RB is a highly radiosensitive tumor. It was once the primary modality of treatment for 
RB, but it was associated with too many side effects. These include cataract formation, 
inflammation of the cornea or conjunctiva, retinopathy, and bleeding (Rao & Hanover, 2017). 
These structures can be seen in Figure 1. Radiation is now only used in refractory cases of RB 
where intravenous chemotherapy has been unsuccessful or in multimodal treatment modalities, 
as it can shrink tumor size and make other treatments more successful (Rao & Hanover, 2017). 
Patients require general anesthesia for this type of treatment, as pediatric patients are unable to 
remain still enough for the duration of the procedure. Therefore, anesthesia providers are 
essential in their care.  
Focal therapy includes cryotherapy, transpupillary thermotherapy, and laser therapy. 
These procedures allow for targeted therapy of smaller tumors, using probes or lasers that are 
able to kill the malignant cells. These options are usually used after tumor size has decreased 
after two to three cycles of chemotherapy or for treatment of small recurrent tumors or subretinal 
seeds (Rao & Hanover, 2017). These cases also require general anesthesia because they are 
painful, and the patient must remain completely still. 
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Enucleation, or the surgical removal of the eye, is the oldest form of treatment for RB. It 
best used for unilateral disease in which the patient has experienced complete loss of vision. This 
can completely remove all of the malignant tumors and immediately cure the patient. However, 
this is now only indicated in advanced cases (Rao & Hanover, 2017). While this is not as 
commonly performed, as other treatment options have been effective in globe salvage, when it is 
done the patient must be under general anesthesia.  
Intraarterial Chemotherapy (IAC) 
Intraarterial chemotherapy is a relatively new procedure that is used as a primary 
treatment of advanced RB or as a secondary treatment in recurrent cases. It has previously been 
described as selective ophthalmic artery chemotherapy or chemosurgery and is performed under 
general anesthesia. Using a sterile technique, a catheter is placed in the femoral artery and 
advanced through the ipsilateral internal carotid artery. The arterial anatomy is visualized with 
angiography and the catheter is then advanced into the ostium of the ophthalmic artery 
(Almontaser et al., 2018). It is there where the chemotherapeutic agent is then injected, as can be 
seen in Figure 4. This allows for selective administration of the chemotherapeutic agent as close 
to the malignancy as possible. 
IAC was first used in the 1950s but is now rapidly becoming a popular treatment option 
for RB. It is particularly useful for advanced stage D and E RB and recurrent RB following 
intravenous chemotherapy. This type of delivery of chemotherapeutic agent minimizes systemic 
toxicity that occurs with intravenous chemotherapy. This is not only because a smaller dose is 
given but also because the selective administration decreases amount systemically absorbed 
(Almontaser et al., 2018). Melphalan and topotecan are the chemotherapeutic agents of choice. 
Melphalan is a cytotoxic nitrogen mustard derivative alkylating agent that inhibits both DNA and 
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RNA synthesis and topotecan is a topoisomerase 
inhibitor that prevents rapidly diving cells from 
repairing DNA damage (Almontaser et al., 2018). The 
specific chemotherapeutic agent used may vary from 
institution to institution and provider preference. 
The efficacy of IAC, however, is largely due to 
a multidisciplinary approach. Patients with RB 
undergoing this type of treatment require frequent 
trips to and evaluations from pediatric oncologists, 
ophthalmologists, interventional neuroradiologists, 
nurse practitioners, and anesthesia providers, 
including nurse anesthetists. It is important that there is an open line of communication among 
all providers involved, particularly during the procedure itself, to ensure both safe delivery of the 
chemotherapeutic agent and proper care of the patient pre, intra, and post procedure. Any 
pertinent information regarding the patient’s care should be well documented. Patients will 
normally receive three treatments within 3- 4-week intervals. Some patients may require as many 
as six treatments to eradicate the entire tumor (Knight, Stiffler, Nixon & Lajoie, 2017). 
Information from all providers should be readily available to their multidisciplinary colleagues. 
This is often attainable through the use of electronic medical records.  
Anesthesia outside of the operating room 
IAC is performed outside of the operating room in interventional neuroradiology. When 
anesthesia is administered in settings outside of the-operating room, anesthesia providers are 
faced with unique challenges that impact patient safety and care. For several reasons, patients 
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under anesthesia in these settings are more likely to suffer from adverse events due to poor 
monitoring. Older anesthesia equipment is often found in these locations and machinery used to 
create images to guide the proceduralist surrounds the patient (Landrigan-Ossar & McClain, 
2014). This forces the anesthesia provider to be further away from the patient than they normally 
would be in the operating room and creates field avoidance. Communication between the 
anesthesia provider and the proceduralist of upmost concern to ensure the safety of the patient.  
In most pediatric hospitals with large caseloads, 30%-40% of cases are performed in non-
operating room anesthesia venues (Nelson & Bailey, 2017). Adverse events may occur in these 
settings that anesthesia providers must be able to anticipate and treat. Contrast media is often 
administered in these procedure areas and patients may develop reactions to this agent. 
Anaphylactoid reactions to contrast media usually occur within five minutes of exposure but can 
also occur within one hour. Patients will present with symptoms, including bronchospasm, 
urticaria, and cardiac instability. Patients at risk for allergic reactions to contrast dye include 
those with asthma, ectopic tendencies, and history of reactions to contrast dye (Nelson & Bailey, 
2017). The anesthesia provider should have all medications to treat such a reaction available to 
him or her in interventional radiology, including epinephrine and intravenous fluids.  
Efficacy of intraarterial chemotherapy 
The side effects of intravenous chemotherapy include neutropenia, deafness, infection, 
and secondary leukemia. Because IAC is selectively administered to the ophthalmic artery, large 
amounts of chemotherapeutic agent do not enter systemic circulation, and therefore these 
unfortunate side effects do not occur. Selective administration also allows the chemotherapeutic 
agent to target the tumor directly. For these reasons, and to maximize the effectiveness of the 
chemotherapeutic agent, IAC is being performed at an increasing frequency (Scharoun, Han, & 
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Gobin, 2016). However, it is important to evaluate whether or not IAC is just as effective as 
intravenous chemotherapy for RB.  
A meta-analysis by Chen et al. (2018) compared the efficacy of IAC to intravenous 
chemotherapy for RB. The authors found there was no statistical difference in globe salvage and 
overall success rate—defined as the avoidance of external beam radiation therapy or enucleation 
in patients with group A, B, C, and E eyes. However, patients with group D eyes who received 
IAC had significantly higher globe salvage rates compared to those who received intravenous 
chemotherapy. There was also a significantly higher rate of globe salvage in stage IV and V eyes 
among those who received IAC compared to intravenous chemotherapy, with no real difference 
in among stage I-III eyes. Between the two groups, there was no difference in tumor recurrence 
or metastasis rates but there was a higher overall success rate in IAC eyes compared to 
intravenous chemotherapy (Chen et al., 2018). This is especially encouraging for patients with 
advanced RB.  
In a retrospective interventional case series by Shields et al. (2014), IAC for RB was 
analyzed as a primary and secondary treatment option after intravenous chemotherapy for 
patients with RB. This study examined a total of 70 eyes in 67 patients with a mean age of 30 
months. Each patient received melphalan, with the addition of topotecan and/or carboplatin as 
necessary. During their follow up, each patient was assessed for regression of the solid tumor, 
subretinal seeds, vitreous seeds, and subretinal fluid. The authors found that globe salvage was 
achieved in 72% of eyes that were treated with primary IAC and 62% of eyes treated with 
secondary IAC (Shields et al., 2014). Eyes that were found to have failed treatment had an 
extensive recurrence of subretinal or vitreous seeds upon examination. Patients who received 
IAC as a secondary treatment option had all either failed intravenous chemotherapy or were 
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facing enucleation as a treatment option. Interestingly, there was no significant difference in 
tumor recurrence found between IAC and intravenous chemotherapy.  
These results support the conclusion that IAC can be an effective treatment option for 
patients, both as a primary and secondary option. The results discussed by Chen et al. (2018) is 
similar to those by Shields et al. (2014), as both authors found higher success rates associated 
with IAC compared to intravenous chemotherapy. Patients may benefit from IAC, not only 
because of its successful outcome, but also because it is not associated with the same systemic 
side effects that accompany intravenous chemotherapy.  
Efficacy in young children  
RB is most frequently diagnosed in children less than 2 years. It may even be present at 
birth and require treatment at a very young age (Grossman & Porth, 2014). This makes it prudent 
to evaluate if IAC is a treatment option for children this young. In a retrospective case study by 
Chen et al. (2016), IAC was found to be effective in children with RB under the age of 3 months. 
The authors studied 10 patients with a mean age of 10.4 weeks who had a total of 28 collective 
procedures. One procedure was canceled after the patient developed an internal carotid artery 
spasm mid procedure. Of the 27 successful procedures, after a follow up of 28.3 months, tumor 
regression was found in 12 out of 13 eyes, all patients were alive, and none of them had 
developed metastatic disease (Chen et al., 2016). This is a relatively short follow up period, so it 
may not provide support for positive long-term outcomes and unfortunately, there are no other 
studies that evaluate IAC for RB in this age group. Furthermore, like most pediatric studies, there 
was no control group. Nonetheless, these results support that IAC is a feasible option even for 
children younger than 3 months old.  
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However, not all patients with primary indications for IAC can actually receive it. In a 
literature review by Manjandavida, Stathopoulos, Zhang, Hanovar, and Shields (2019), the 
following are listed as contraindications: 1) patients with neovascular glaucoma, orbital cellulitis, 
hyphema or blood in the anterior chamber of the eye, 2) evidence of optic nerve, scleral, orbital 
or extraocular extension, 3) trilateral RB, 4) systemic metastasis, 5) tumors that may benefit from 
transpupillary cryotherapy, and/or intravitreous chemotherapy.  
Pediatric anesthesia for IAC for RB 
Patients require general anesthesia with endotracheal intubation and muscle relaxation to 
undergo IAC as they must remain completely still as the neuroradiologist guides a catheter into 
their ophthalmic artery under fluoroscopic visualization. Scharoun et al. (2016) discusses the 
anesthetic techniques used by anesthesia providers at Weil Cornell Medical Center in New York, 
New York. General anesthesia can be maintained with volatile anesthetic and patients are 
mechanically ventilated using pressure control ventilation. Most importantly, the anesthesia 
provider must ensure complete immobility of the patient during catheter manipulations by the 
proceduralist. After intubation, oxymetazoline, a potent vasoconstrictor, is sprayed into the nare 
ipsilateral to the tumor. This causes constriction of vessels in the nose, to ensure that the 
chemotherapeutic agent stays in the ophthalmic artery and does not pass into collateral 
circulation. Dexamethasone is given to prevent periorbital edema if two chemotherapeutic agents 
are administered. Heparin is then administered by the anesthesia provier after the femoral 
catheter is placed by the proceduralist.  
Once the procedure is completed, dexmedetomidine may be given after the femoral 
catheter is removed. The patient needs to remain supine without bending his or her leg to prevent 
hematoma formation over the femoral cannula site. Dexmedetomidine can be an excellent 
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sedative for this as it preserves respiration, unlike opioids which depress respirations. Muscle 
relaxation reversal should then be administered. Patients are then extubated and transported to 
PACU (Scharoun et al., 2016). Anesthesia providers should bring emergency medications and 
supplies for reintubation during transport if PACU is not in close proximity to interventional 
radiology.  
Complications of IAC 
The concept of delivering a chemotherapeutic agent through the ophthalmic artery to 
target the tumor is to limit the amount of agent delivered systemically. The previously discussed 
side effects associated with intravenous chemotherapy has pushed the new interest in 
implementing IAC as a primary treatment for RB (Monroy et al., 2014). However, IAC, like all 
RB treatments, is not a benign procedure and comes with its own effects and complications. 
  The intraocular complications with IAC discussed by Monroy et al. (2014), include 
ophthalmic artery thrombosis, retinal and vitreous hemorrhages, enucleation, orbital edema, 
retinal detachment, third cranial nerve palsy, and retinal pigment changes. The extraocular 
complications include transient femoral artery occlusion due to thrombus at the catheter insertion 
site and periocular erythema. There have also been reports of reversible cerebral 
vasoconstriction, but this may have been due to other pharmacologic agents administered during 
the procedure, including oxymetazoline, mydriatics that contain phenylephrine, and albuterol. 
Despite its occurrence, no permanent sequelae have been reported from cerebral 
vasoconstriction. The most serious and pertinent extraocular complication reported by Monroy et 
al. (2014) is the transient hemodynamic instability and abrupt decrease in ventilation associated 
with ophthalmic artery cannulation. This cardiorespiratory event is the most important IAC side 
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effect for anesthesia providers to be aware of, as they need to be able to identify and treat it if it 
occurs.  
Decreased Pulmonary Compliance During IAC for RB 
When undergoing IAC for RB, patients may experience a sudden and profound decrease 
in pulmonary compliance. Patients become difficult to ventilate and develop hypoxemia very 
rapidly. Following this decrease in compliance, patients experience hemodynamic changes that 
may lead to adverse outcomes, including death, if not treated appropriately (Scharoun et al., 
2016.). Pediatric respiratory physiology may contribute to the sudden and profound 
cardiovascular manifestations.    
Pediatric Vulnerability to Hypoxia 
According to Hines & Marshall (2018), there are very important physiological 
differences between the adult and pediatric respiratory systems that make pediatric patients 
extremely vulnerable to life threatening problems if a decrease pulmonary compliance occurs. 
First, a pediatric patient’s oxygen consumption is two times greater than an adult on a per 
kilogram basis. This contributes to a rapid onset of hypoxemia when ventilation is compromised. 
Second, pediatric patients have higher compliance of their chest wall and lung parenchyma. This 
is especially true in newborns and predisposes them to alveolar collapse. Chest wall compliance 
is higher in the newborn because there is less ossification of their ribcage. This means that at the 
end of exhalation, the “spring” of the chest wall pulling outward to create the negative pressure 
that begins inhalation, is much weaker in a child than an adult. This causes a child’s functional 
residual capacity, which is the volume of air in the lung at the end of passive exhalation, to be 
much closer to closing capacity, which is the volume in the lungs at which the respiratory 
bronchioles collapse (Bhalla, Khemani, & Newth, 2017). Therefore, at the end of expiration, 
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small airways of the lung collapse and alveoli are not ventilated. This leads to a ventilation to 
perfusion mismatch and results in hypoxemia very quickly. Adults, however, do have excellent 
elasticity of their chest wall, and therefore and increased functional residual capacity compared 
to an infant or a child (Hines & Marshall, 2018). Extensive knowledge of pediatric respiratory 
physiology compared to that of the adult is crucial for pediatric anesthesia providers in providing 
safe anesthetics.  
Presentation of Decreased Pulmonary Compliance  
In a case report by Scharoun et al. (2016), the authors present a 2-year-old boy 
undergoing IAC for RB. The patient was placed under general anesthesia with muscle relaxation 
and mechanical ventilation. The femoral artery was cannulated, and the catheter advanced 
toward the internal carotid artery, the catheter was then further advanced to the orifice of the 
ophthalmic artery. This can be identified in Figure 4. At this time, the anesthesia provider 
noticed a sudden drop in tidal volume by 75%. Upon auscultation, there is no wheezing 
appreciated. Albuterol, however, was still administered. There was little improvement in tidal 
volume and the patient began to desaturate. The anesthesia provider then hand ventilated the 
patient, and after 3 minutes his tidal volumes began to recover. However, the patient then 
becomes bradycardic and hypotensive requiring epinephrine. After several doses, as well as 
crystalloid fluid administration for blood pressure support, the patient stabilized. The procedure 
continues, the patient is extubated, and recovered in the PACU unremarkably.  
This cardiopulmonary event occurs in as much as 29% of IAC cases, despite the level of 
anesthesia or muscle relaxation (Scharoun et al., 2016). The phenomenon even occurs before 
anything is injected into the ophthalmic artery, including saline, contrast, or chemotherapeutic 
agent. It is always abrupt and is related to the initial positioning of the catheter in the internal 
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carotid artery or the ophthalmic artery. Tidal volumes will decrease, and patients will quickly 
desaturate due to the normal pediatric lung physiology that was discussed earlier. This may lead 
to bradycardia, hypotension, and cardiovascular collapse (Scharoun et al., 2016). This event must 
be quickly identified by the anesthesia provider and treated appropriately.  
Risk Factors for Developing a Decrease in Pulmonary Compliance During IAC for RB  
  As this is now a well-known occurrence with IAC, the question remains—who is at risk 
and can the depth of anesthetic effect its occurrence? In a retrospective study by Phillips et al. 
(2013), a total of 52 patients underwent a combined 143 rounds of intra-arterial chemotherapy. 
Each patient received super selective ophthalmic artery chemotherapy using a standard protocol 
for general anesthesia, ophthalmic artery catheterization, and pulsed infusion of melphalan as the 
chemotherapeutic agent. All patients were intubated and received volatile anesthetic with muscle 
paralysis. Patients who required treatment intraoperatively to maintain cardiac and respiratory 
stability were considered to have had an adverse reaction.  
Adverse reactions occurred in 35 of the procedures, or 24% of cases (Phillips et al., 
2013.) This finding is similar to the occurrence of 29% of cases as cited by Scharoun et al. 
(2016). All of the documented reactions occurred during the second or subsequent 
catheterization procedure and consisted of hypoxia, reduced lung compliance, systemic 
hypotension, and/or bradycardia. Out of the 143 procedures, only one was abandoned due to 
hemodynamic instability.  
Two patients were discussed specifically by Phillips et al. (2013). In the case of a 15- 
month-old child weighting 11 kg, undergoing their second intraarterial chemotherapy procedure, 
immediately after microcatheter was flushed with 0.9% normal saline the patient experienced a 
40% decrease in tidal volume from 130 mL to 70 mL. Following this decrease in lung 
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compliance the patient’s blood pressure decreased from 80/50 (58) mmHg to a minimum of 
43/16 (25) mmHg. Additionally, the heart rate decreased from 160 to 141 bpm. The second 
patient was a six-year-old child weighing 25 kg undergoing their fifth procedure, immediately 
upon insertion of the microcatheter into the ophthalmic artery, the patient’s tidal volume 
decreased from 247 to 22 mL—a 90% decrease. Following this event, the patient experienced a 
decrease in blood pressure from 92/42 (57) mmHg to a nadir of 52/24 (32) mmHg (Phillips et al., 
2013). Specific end-tidal CO2 and peak airway pressure readings were not discussed in these 
cases, but this illustrates how drastic the hemodynamic changes can be during this procedure 
upon catheter insertion and manipulation.  
Phillips et al. (2013) concluded that: 1) The clinical signs present in these patients are 
believed to be an autonomic reflex, similar to the TCR or oculocardiac reflex. 2) All of the 
documented reactions occurred during the second or subsequent procedures. This means that 
patients may become sensitized during initial procedures and then the phenomenon is evoked 
with subsequent procedures. 3) Finally, atropine does not alter the incidence or severity of these 
reactions. 4) These reactions are life-threatening.   
Data from other studies, however, have countered the conclusion that patients become 
sensitized and only experience this autonomic respiratory compromise on subsequent 
procedures. In a retrospective study by Kato et al. (2014), 122 patients undergoing a total of 468 
procedures were studied. Intraoperative peak inspiratory pressure, positive end-expiratory 
pressure, tidal volume, oxygen saturation, and end-tidal carbon dioxide were analyzed. Any 
change in compliance, decrease in end-tidal carbon dioxide, and clinical outcomes were 
assessed. Compliance was defined as (∆ volume/∆  pressure) and computed as tidal volume/ 
(peak inspiratory pressure- positive end expiratory pressure). Out of the entire subject 
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population, 64% experienced a severe compliance event which was defined as a decrease in lung 
compliance of 40% (Kato et al., 2014). This means that if a 20 kg child had a normal tidal 
volume of 120-180 mL (6-8 ml/kg), their tidal volume would drop to as low as 72-108 mL. In 
the group of patients that experienced a severe respiratory compliance event, 20% experienced 
oxygen desaturation below 90%. Six of these patients experienced desaturation below 60%. 
Similarly, a sudden drop of end-tidal CO2 by 30% occurred in 34% of patients in this subset 
(Kato et al., 2014). These are very dramatic hemodynamic changes that would be of upmost 
concern to the anesthesia provider.   
Out of the 122 patients in this study, 27% experienced this significant decrease in 
compliance during their first exposure and 73% experienced the event in a subsequent case. Out 
of a subset of 94 patients who had their first and subsequent procedures identified, 67% 
experienced at least one severe respiratory event. Of this 67%, 18% of patients experienced a 
decrease in compliance during their first procedure (Kato et al., 2014). While the first case 
incidence is much smaller than subsequent case incidence, this finding rebuttals Phillips et al. 
(2013) conclusion that patients become sensitized to the phenomenon after their first procedure. 
Kato et al. (2013) also found that the respiratory compromise is abrupt and always temporarily 
related to the initial positioning of the catheter in the internal carotid artery or the ophthalmic 
artery. This was found to be the case in every procedure where a respiratory event occurred.  
The authors concluded that occurrence of a cardiopulmonary events during the first 
procedure is not predictive of it reoccurring in subsequent procedures. However, these events 
occur at a predictable stage of the procedure and are self-limiting (Kato et al., 2014). This allows 
the anesthesia provider to be prepared for when a decrease in compliance does occur so they can 
properly manage it. There should always be clear and open communication between the 
ANESTHETIC IMPLICATIONS OF INTRAARTERIAL CHEMO 23 
anesthesia provider and neuroradiologist, so when this event does occur, the neuroradiologist can 
be notified and pause catheter manipulations until the problem resolves. Patients should 
immediately be placed on 100% oxygen and hand ventilated by the anesthesia provider (Kato et 
al., 2014). The authors also suggest that this most likely occurs due to a vascular to pulmonary 
reflex, which has not been described yet. While other reports suggest it is due to the oculo-
cardiac reflex or trigemino-cardiac reflex, Kato et al. (2014) disagrees. 
A retrospective study by Harris & Gaynor (2014) described what they believe is the TCR 
occurrence in patients undergoing IAC for RB and the objective change in compliance and vital 
signs experienced by those with a positive TCR. Harris & Gaynor (2014) studied 49 patients who 
underwent a collective 199 procedures. The authors define a positive TCR as the presentation of 
two of the following clinical features: 1) drop in systolic, diastolic, and/or mean blood pressure 
by 20% or greater, 2) a drop in pulse oximetry reading of 20% or greater, 3) a decrease in end-
tidal carbon dioxide measurement of 20% or greater, indicative of a severe decrease in 
ventilation related to perfusion, and 4) an increase in peak inspiratory pressure of 20% or greater.  
Harris & Gaynor (2014) found a total of 28 TCR events occurred in 18 out of 49 patents 
undergoing IAC for RB. In 21 of these cases, the TCR occurred during angiography of the 
ophthalmic artery and in seven cases it occurred during flushing or infusion through the catheter. 
The TCR did not occur during insertion of the catheter into the internal carotid artery or 
cavernous sinus, but only during microcatheter insertion into the ophthalmic artery. Only one of 
the TCR events was prolonged as it lasted three minutes and the procedure was aborted. All 
other cases were transient, and the procedure was able to continue after the stabilization of vital 
signs. Out of the 28 cases, seven received one dose of phenylephrine (1 mcg/kg) to support their 
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blood pressure and two patients received epinephrine (1 mcg/kg), not only to support blood 
pressure but to also produce bronchodilation (Harris & Gaynor, 2014).   
This study found that among all cases with a positive TCR, 85.7% experienced a rise in 
peak inspiratory pressure, 75% experienced a decrease in their end-tidal carbon dioxide, and 
64.3% experienced a decrease in their systolic blood pressure. The average rise in peak 
inspiratory pressure among all cases was 83.3% (Harris & Gaynor, 2014). This means that if a 
patient had a normal peak inspiratory pressure of 18 cm H20, then an 83.3% increase would 
calculate to be 33 cm H20. This is a notable increase that would be concerning to anesthesia 
providers, especially if the patient was paralyzed, not experiencing a change in position, and not 
coughing. The average drop in end-tidal CO2 among all cases was by 37.4% (Harris & Gaynor, 
2014). This means that a normal reading of 40 mmHg would decrease to 25 mmHg. This would 
also be very concerning to anesthesia providers as it indicates a severe decrease in perfusion or 
ventilation. Finally, systolic blood pressure decreased by an average of 26.4% (Harris & Gaynor, 
2014). To put this into context, a normal systolic blood pressure in a 5-year-old would be 100 
mmHg. Of course, under general anesthesia, it may be lower, but a 26.4% decrease from a 
systolic blood pressure reading of 100 mmHg would be 74 mmHg. Also, a very concerning sign 
for an anesthesia provider.  
These studies tell the reader four things. First, a decrease in pulmonary compliance may 
occur during IAC in 24-29% of cases. Second, all patients undergoing IAC for RB are at risk of 
this event, whether it’s the patients first or subsequent treatment. Third, the timing of the event is 
predictable, and will most likely occur during cannulation of the ophthalmic artery. Fourth, this 
event is usually transient, but emergency medications, including phenylephrine and epinephrine 
should be readily available.  




As the trigemino-cardiac reflex (TCR) and the oculo-cardiac reflex have both been 
mentioned in studies and publications describing the pulmonary compromise in patients 
undergoing IAC for RB, it is important to discuss and define the reflexes. In an article by 
Meuwly et. al (2017), the authors' goal was to improve the definition of the trigemino-cardiac 
reflex. They found that the TCR is triggered by a physical and/or chemical stimulation of any 
part or branch or the fifth cranial nerve, also known as the trigeminal nerve. Once these nerves 
are activated, an afferent signal is sent to the sensory nucleus of the trigeminal nerve, which is 
located on the floor of the fourth ventricle. The afferent pathway is connected to the efferent 
pathway via the reticular formation. The efferent premotor neurons are located in the nucleus 
ambiguous and the dorsal motor nucleus of the vagus nerve. These fibers activate the 
cardioinhibitory parasympathetic fibers which cause the clinical symptoms.  
A positive TCR is defined as a sudden drop in heart rate and mean arterial blood 
pressure. The authors defined the TCR as having two major (plausibility and reversibility) and 
two minor (repetition and prevention) criteria. There has to be a direct link of time and action 
between stimulation and clinical manifestations and termination of the stimulus should also cease 
the manifestations (Meuwly et. al, 2017). The minor criteria suggest that the reflex should occur 
every time the stimulus is repeated. Due to ethical reasons, this is not something that can be done 
in every TCR case.  
Chowdhury & Schaller (2016) define the TCR as a sudden onset of bradycardia with 
associated hypotension, apnea or gastric hypermotility during stimulation of any of the sensory 
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branches of the trigeminal, or fifth cranial nerve. The decrease in heart rate and blood pressure 
must be more than 20% from baseline and must be due to manipulation of the trigeminal nerve 
during surgery. Symptoms are transient when stimulation is removed (Chowdhury & Schaller, 
2016). The authors presented four cases in which they believe the symptoms exhibited by the 
patient were due to the TCR. Only two of the cases will be included in this paper, due to a lack 
of relevance in the remaining cases. Neither of the cases that will be presented was due to IAC, 
but for this paper, the role of the TCR in their outcomes will be discussed.  
The first two cases presented by Chowdhury & Schaller (2016) identify nasal packing to 
treat epistaxis as the precipitating factor before developing bradycardia, respiratory distress with 
a concomitant decrease in oxygen saturation, and hypotension. Both patients were intubated and 
provided advanced cardiac life support. Both patients, unfortunately, died as a result. 
Interestingly, nasal packings were not removed during resuscitation. This highlights that the TCR 
is not just limited to direct surgical stimulation and can result from indirect manipulation of the 
trigeminal nerve (Chowdhury & Schaller, 2016). Either direct or indirect, the TCR can be 
devastating if not treated appropriately, leading to death.  
While this case series is very limited with its small sample size and lack of evidence if 
the nasal packings were the exact cause, it highlights the importance of the occurrence of 
identifying the TCR and treating it appropriately.   
In a case study published by Klumpp, Jorge, and Azix-Sultan (2013), a 2-year-old 
presenting with RB in his right eye was referred for IAC using melphalan. After general 
anesthesia was induced, the patient was given muscle paralysis, intubated, and ventilated using 
pressure-controlled ventilation. Sevoflurane was used to maintain general anesthesia, mixed with 
50% oxygen and air. After his femoral artery was cannulated, a microcatheter was advanced 
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through the internal carotid artery and into the ostium of the ophthalmic artery. Two minutes 
later, the patient's end-tidal CO2 decreased by 14 mmHg and the patient experienced a 
precipitous fall in his oxygen saturation to a nadir of 40%. The anesthesia provider alerted the 
neuroradiologist who withdrew the catheter and the patient was ventilated with 100% oxygen. 
Wheezing was not heard upon auscultation. After four minutes, end-tidal measurements returned 
to normal, but the patient became hypotensive and phenylephrine (2 mcg/kg) was administered 
along with a fluid bolus over 30 minutes. Once the patient was stabilized the neuroradiologist 
was able to continue with the procedure without any further adverse events.  
While there was no discussion of the adequacy of tidal volume administration during the 
time of this hemodynamic instability, the decrease in end-tidal CO2 is indicative of dead space 
ventilation (Klumpp, Jorge, and Azix-Sultan, 2013). The patient was noted to become 
tachycardic, not bradycardic as previous other studies have mentioned. And therefore, we cannot 
say that this patient experienced the trigemino-cardiac reflex. Klumpp et al. (2013) continue to 
account that in their series of case studies evaluating this phenomenon, it occurred among 8 out 
of 30 patients of which experienced similar responses. Not one of their patients ever became 
bradycardic and therefore the TCR cannot be blamed.  
This literature does not support that the TCR is what occurs during IAC. Based on the 
research conducted for this paper, it seems that bradycardia associated with IAC is directly 
related to an inability to ventilate, causing hypoxia, and resulting in bradycardia. So why is the 
TCR being blamed? And if it is not the TCR causing these symptoms, then what is? 
Unfortunately, the afferent and efferent signaling for this phenomenon has not been established, 
and the reason as to why this happens remains unknown.   
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Diving Reflex  
Another autonomic reflex that may explain this cardiorespiratory event, is the diving 
reflex. Out of all the research conducted for this literature review, the diving reflex was only 
briefly mentioned by Scharoun et al. (2017). Most mammals have an intact diving reflex. It 
triggered by immersion of the face in cool 
water and is a protective mechanism to 
prevent aspiration while underwater. This 
reflex results in bradycardia, apnea, and 
peripheral vasoconstriction. While 
bradycardia occurs with immersion, alone, it 
is even further exaggerated by simultaneous 
apnea. This reflex is mediated by the 
ophthalmic branch of the fifth cranial nerve, 
or trigeminal nerve, via the anterior ethmoid 
nerve (Scharoun et al., 2017.) Studies 
mentioned by Scharoun et al. (2017) have 
found that direct stimulation of the anterior 
ethmoid nerve in muskrats causes bradycardia, hypotension, and apnea. This pathway can be 
seen in Figure 5. Interestingly, cutting the anterior ethmoid nerve completely abolishes the apnea 
triggered by nasal stimulation. According to Scharoun et al. (2017), anesthetized and 
spontaneously breathing dogs experience a decrease in dynamic lung compliance from 25.5 to 
13.7 mL/cm H2O and decrease in heart rate when given intranasal capsaicin. Could this be what 
is occurring in patients undergoing IAC for RB? It is unclear. It is also not mentioned in any 
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other literature related to IAC for RB, except for the case report by Scharoun et al. (2017). More 
research is needed to determine if this is the cause of the sudden cardiorespiratory event during 
IAC for RB.  
Anesthetic Influence 
The previously mentioned studies all conclude that a decrease in respiratory compliance 
does indeed occur during ophthalmic artery chemotherapy for RB. It is presumed this is due to 
some sort of autonomic reflex, but the exact mechanism remains unclear. None of these studies, 
however, have evaluated what anesthetic factors may attribute to this occurrence. In a 
prospective, observational, single-arm study by Nghe et al. (2018), the authors hypothesized that 
the level of anesthetic depth may influence the occurrence of this respiratory phenomenon. A 
total of 115 procedures were analyzed on 32 patients. Other variables, including age and weight, 
medical history of asthma or upper respiratory tract infection within four weeks, and exposure to 
secondhand smoke were also assessed in hopes to find a possible association with severe 
intraoperative cardiopulmonary events.  
Nghe et al. (2018) defined severe cardiorespiratory events as arterial hypotension, 
bradycardia, and a severe decrease in lung compliance. Out of the 115 procedures, 24 resulted in 
adverse cardiorespiratory events—20 experienced a severe decrease in lung compliance, one 
experienced bradycardia, and arterial hypotension was seen in nine procedures. All events 
occurred within two minutes of catheter insertion into the ophthalmic artery with a median 
occurrence of one minute. No events occurred while the catheter was in the carotid artery or after 
chemotherapy injection. For patients that experience a severe decrease in lung compliance, their 
peak inspiratory pressures gradually rose within the first minute of catheter insertion. Following 
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this rise, oxygen saturation decreased and some experienced hemodynamic instability (Nghe et 
al., 2018).  
Unfortunately, none of the demographic data or medical history was significant in 
association with serious adverse cardiorespiratory events. Furthermore, all patients were 
maintained under general anesthesia using sevoflurane with mean alveolar concentration (MAC) 
values between 1.5 and 1.7, high enough to blunt autonomic reflexes. Patients also received a 
bolus of sufentanil 0.2 mcg/kg on induction and additional boluses of 0.1 mcg/kg after femoral 
artery puncture. Their bispectral index (BIS) was maintained between 40-50, a value 
encouraging of adequate depth of general anesthesia (Nghe et al., 2018).  
Nghe et al. (2018), concluded that neither demographic values nor medical history can 
predict the occurrence of severe cardiorespiratory events during ophthalmic artery 
chemotherapy. Furthermore, this phenomenon can occur despite an adequate depth of general 
anesthesia, in which autonomic reflexes should be attenuated.  
Treatment of Intraoperative Decrease in Pulmonary Compliance During IAC for RB 
While the actual physiology of what causes the decrease in pulmonary compliance during 
IAC for RB is unknown, the treatment of possible physiological mechanisms will be discussed. It 
is speculated that patients may develop acute bronchospasm due to stimulation of the ophthalmic 
artery, causing a decrease in respiratory compliance due to the TCR. This causes a release of 
acetylcholine on the muscarinic receptors on the bronchial smooth muscle, resulting in 
bronchoconstriction. However, studies have documented the lack of wheezing heard upon 
auscultation and furthermore the administration of bronchodilators, like albuterol, do not 
improve symptoms. Pediatric intraoperative bronchospasm has an occurrence rate of 0.2-4.1% in 
the general population. There are three major triggers for perioperative bronchospasm including 
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mechanical airway manipulation, anaphylactoid reactions, and immunological anaphylaxis. 
Treatment includes reducing the level of stimulus, deepening the anesthetic, and administration 
of 100% oxygen. Pharmacologic intervention includes the administration of beta-2 agonists like 
albuterol. If severe airflow limitation persists, intravenous beta-2 agonists like salbutamol and 
epinephrine can be administered. Other medications include atropine, glycopyrrolate, and 
magnesium, all of which may provide further bronchodilation. Anesthesia providers should do 
their best to provide protective lung ventilation and avoid high peak airway pressures to avoid 
hyperinflation and barotrauma (Regli & von Ungern-Sternberg, 2015).  
Anesthetic Management of Patients with RB  
 Some level of sedation or general anesthesia is needed for the large array of treatment 
options for RB. Therefore, anesthesia providers are becoming more involved in the care of 
patients with RB as IAC is becoming a more frequently used treatment option for these patients. 
Not only do anesthesia providers need to be well versed in the physiology of the disease but they 
also need to well-educated on the potential complications that can occur intraoperatively. The 
decrease in pulmonary compliance associated with ophthalmic artery cannulation is well 
reported with occurrence rates of 24-29%. Anesthesia providers should anticipate this event to 
occur with every anesthetic provided for IAC for RB and have the available tools to treat these 
patients readily available.  
The Johns Hopkins Hospital IAC for RB and Pediatric Anesthesia  
 At The Johns Hopkins Hospital in Baltimore, Maryland, IAC is a commonly 
administered treatment for RB. Pediatric anesthesia providers are well educated on the disease 
and pulmonary manifestations that may occur during the procedure. Dr. Monica Pearl is a 
neuroradiologist at JHH and administers IAC to this patient population. From an anecdotal 
ANESTHETIC IMPLICATIONS OF INTRAARTERIAL CHEMO 32 
perspective, Dr. Pearl discusses the decrease in pulmonary compliance that occurs during this 
procedure during her “time out”. She instructs the anesthesia provider to immediately let her 
know if this event occurs so that she can retract the cannula from the ophthalmic artery and halts 
the procedure until the patient recovers. Anesthesia providers prepare a syringe of epinephrine 
diluted to 10 mcg/ml and are prepared to administer it immediately if this event occurs. All 
patients are maintained under general anesthesia with sevoflurane and maintain muscle paralysis 
with rocuronium. Mechanical ventilation is supported with pressure support ventilation so that if 
there is a decrease in pulmonary compliance, the anesthesia provider can be immediately alerted 
when there is a decrease in tidal volume. This open line of communication between the 
proceduralist and the anesthesia provider ensures that everyone in the room is educated and 
prepared for this intraoperative event and have the ability to treat it immediately. This is exactly 
what Dr. Monica Pearl does during her “time out.” 
Conclusion 
 RB is a difficult diagnosis for a family to deal with. New therapies like IAC provide 
treatment options that are just as effective as intravenous chemotherapy with far fewer side 
effects. While these patients do not suffer from the nephrotoxicity, hepatotoxicity, 
cardiomyopathy, ototoxicity, and myelosuppression associated with intravenous chemotherapy, 
it is far from a benign procedure. The intraoperative cardiorespiratory event associated with IAC 
can be devastating. However, it can be anticipated by anesthesia providers and treated 
effectively. This can only be attainable by educating the anesthesia provider on how to prepare, 
anticipate, identify, and treat this event effectively.  
 While the exact mechanism that causes such profound cardiorespiratory event during 
IAC for RB is not fully known, it is important for the anesthesia provider to be aware that its 
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occurrence is a possibility. Further research should be aimed at identifying risk factors for 
developing this adverse event as well as the impact of the anesthetic provided. Furthermore, if 
this is an autonomic mechanism, research should be aimed at identifying the afferent and efferent 
limbs. In the meantime, providers should be aware that when the event does occur, it is prudent 
to have an open line of communication with the neuroradiologist. When the catheter 
manipulation is stopped, the symptoms usually resolve. As always, patients’ hemodynamics 
should be supported by the anesthesia provider throughout the case, and emergency medications 
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